Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

BiltRx vs Maves

BiltRx
Graded #58

Higher grade

vs+3.4000000000000057
Maves
Graded #91

Lower grade

The verdict

BiltRx takes it — 75/100 to 71.6/100.

BiltRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. BiltRx is a US health-optimization telehealth platform spanning men's health, women's health, aesthetics and weight loss that offers compounded and brand-name GLP-1 medications.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBiltRx +7
90
83
Dose & formulationBiltRx +20
85
65
Clinical oversightMaves +2
74
76
Labs & monitoringEven
52
52
FulfillmentMaves +16
71
87
Contract termsEven
55
55
BiltRx · left barMaves · right bar

The numbers

MetricBiltRxMaves
WeighScore75/10071.6/100
GradeCC
Scorecard rank#58#91
Semaglutide$125/mo (all doses, compounded)$99/mo (starting dose, first-month rate, compounded)
Tirzepatide$129/mo (all doses, compounded)Not disclosed
CoverageCoverage not publishedAll 50 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
BiltRx

Graded #58 · C

Strengths

  • Very low starting prices (semaglutide from 125 dollars, tirzepatide from 129 dollars)
  • LegitScript verified and HIPAA compliant
  • Names its 503A compounding pharmacies (Boothwyn and Southend)
  • Offers both compounded and brand-name GLP-1 options

Where it loses points

  • Covered states are behind a check-availability gate, not listed
  • Starting prices may rise depending on plan and dose
Maves

Graded #91 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard